On July 16, Elevance Health fell 3.03% in regular trading, trading at $371.91/share, with turnover of $223 million. The stock extended its decline from the prior session following the Q2 earnings release on July 15.

On the news front, while Q2 adjusted EPS of $7.45 beat consensus of $6.21 by approximately 20% and revenue of $49.83 billion exceeded estimates by $1.2 billion, operating margin contracted sharply from 4.9% to 3.5% year-over-year, and EPS declined 15.72% from the prior-year period. The company raised full-year adjusted EPS guidance only modestly to at least $27, barely above the $26.87 consensus. Additionally, the CEO disclosed plans to exit more state Medicaid markets over the next 12 to 18 months, highlighting structural profitability concerns in that segment. Rising costs in autism treatment, emergency room usage, outpatient surgery, and specialty drugs further weighed on sentiment. Notably, peer UnitedHealth gained 5.75% on the same day, underscoring ELV-specific margin and business-mix headwinds driving the divergence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)